This is a prospective non-randomized trial with two study groups. The trial is designed to show if the ARTERY FIRST approach reduces the rate of R1 resections in patients undergoing surgery for cancer of the pancreatic head.
After the diagnosis of cancer of the pancreatic head by clinical, laboratory and imaging evaluation patients who are scheduled for resection will be screened for inclusion into the trial. Informed consent is obtained at least on the day before surgery and patients meeting the eligibility criteria will be enrolled into the study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pancreatic head cancer (diagnosis by clinical, laboratory and radiological evaluation)
Patients scheduled for curative resection
No evidence of distant metastases
Age equal or greater than 18 years
Informed consent
You may not be if
Expected lack of compliance
Impaired mental state or language problems
patient having had neoadjuvant radiochemotherapy
Clareo Health | The ARTERY FIRST Approach for Resection of Pancreatic Head Cancer
